Mitochondrial mechanisms in amyloid beta peptide-induced cerebrovascular degeneration

Biochimica et Biophysica Acta - General Subjects

Volumn 1800, Issue 3, 2010, Pages 290-296

  Hsu, Ming Jen ^a   Sheu, Joen Rong ^a   Lin, Chien Huang ^a   Shen, Ming Yi ^a   Hsu, Chung Y ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Aging; Amyloid beta peptide; Apoptosis; Ceramide; Cerebrovascular disease; Endothelial cells; Mitochondria; Stroke

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOPTOSIS INDUCING FACTOR; APOPTOSIS SIGNAL REGULATING KINASE 1; BIM PROTEIN; CERAMIDE; CYTOCHROME C; ENDONUCLEASE G; GLYCOGEN SYNTHASE KINASE 3BETA; MITOCHONDRIAL DNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN BAD; PROTEIN BAX; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FKHRL1; X LINKED INHIBITOR OF APOPTOSIS;

AGING; ALZHEIMER DISEASE; APOPTOSIS; ASTROCYTE; BRAIN MITOCHONDRION; CELL DEATH; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; DNA DAMAGE; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; NERVE CELL NECROSIS; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TRANSPORT; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TRANSACTIVATION; VASCULAR AMYLOIDOSIS; CONFERENCE PAPER; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; MITOCHONDRION; NERVE CELL DEGENERATION; PROTEIN FAMILY;

AGED; AGING; AMYLOID BETA-PROTEIN; ATHEROSCLEROSIS; CELL DEATH; CERAMIDES; DEMENTIA, VASCULAR; HUMANS; MIDDLE AGED; MITOCHONDRIA; NERVE DEGENERATION; OXIDATIVE STRESS; SENILE PLAQUES; SPHINGOMYELIN PHOSPHODIESTERASE; STROKE; WORLD HEALTH ORGANIZATION;

EID: 76749138927     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2009.08.003     Document Type: Review

References (135)

1. Choi J.Y., Morris J.C., and Hsu C.Y. Aging and cerebrovascular disease. Neurol. Clin. 16 (1998) 687-711
2. Wolf P.A., Mitchell J.B., Baker C.S., Kannel W.B., and D'Agostino R.B. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch. Intern. Med. 158 (1998) 229-234
3. Burke M.J., Banks W.J., Nelson A.W., and Seim H.B. Histochemical study of the anulus fibrosus in normal canine caudal cervical intervertebral discs. Res. Vet. Sci. 40 (1986) 18-23
4. Hatake K., Kakishita E., Wakabayashi I., Sakiyama N., and Hishida S. Effect of aging on endothelium-dependent vascular relaxation of isolated human basilar artery to thrombin and bradykinin. Stroke 21 (1990) 1039-1043
5. Kalaria R.N., and Harik S.I. Carnitine acetyltransferase activity in the human brain and its microvessels is decreased in Alzheimer's disease. Ann. Neurol. 32 (1992) 583-586
6. Hsu C.Y., and Hu Z.Y. Vascular pathology in the elderly. Eur. Neurol. 35 Suppl 1 (1995) 2-4
7. Kalaria R.N. Cerebral vessels in ageing and Alzheimer's disease. Pharmacol. Ther. 72 (1996) 193-214
8. Mentis M.J., Horwitz B., Grady C.L., Alexander G.E., VanMeter J.W., Maisog J.M., Pietrini P., Schapiro M.B., and Rapoport S.I. Visual cortical dysfunction in Alzheimer's disease evaluated with a temporally graded "stress test" during PET. Am. J. Psychiatry 153 (1996) 32-40
9. Kalaria R.N., and Hedera P. beta-Amyloid vasoactivity in Alzheimer's disease. Lancet 347 (1996) 1492-1493
10. Kalaria R.N. Cerebrovascular degeneration is related to amyloid-beta protein deposition in Alzheimer's disease. Ann. N. Y. Acad. Sci. 826 (1997) 263-271
11. Gearing M., Tigges J., Mori H., and Mirra S.S. beta-Amyloid (A beta) deposition in the brains of aged orangutans. Neurobiol. Aging 18 (1997) 139-146
12. Walker L.C. Animal models of cerebral beta-amyloid angiopathy. Brain Res. Brain Res. Rev. 25 (1997) 70-84
13. Tamaoka A., Kalaria R.N., Lieberburg I., and Selkoe D.J. Identification of a stable fragment of the Alzheimer amyloid precursor containing the beta-protein in brain microvessels. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 1345-1349
14. Buee L., Hof P.R., Bouras C., Delacourte A., Perl D.P., Morrison J.H., and Fillit H.M. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol. 87 (1994) 469-480
15. Kalaria R.N., and Hedera P. Differential degeneration of the cerebral microvasculature in Alzheimer's disease. NeuroReport 6 (1995) 477-480
16. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28 (2005) 202-208
17. Chow N., Bell R.D., Deane R., Streb J.W., Chen J., Brooks A., Van Nostrand W., Miano J.M., and Zlokovic B.V. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 823-828
18. Bell R.D., Deane R., Chow N., Long X., Sagare A., Singh I., Streb J.W., Guo H., Rubio A., Van Nostrand W., Miano J.M., and Zlokovic B.V. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat. Cell Biol. 11 (2009) 143-153
19. Pasquier F., Leys D., and Scheltens P. The influence of coincidental vascular pathology on symptomatology and course of Alzheimer's disease. J. Neural. Transm. Suppl. 54 (1998) 117-127
20. Van Broeckhoven C., Haan J., Bakker E., Hardy J.A., Van Hul W., and Wehnert A. M. Vegter-Van der Vlis, R.A. Roos, Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science 248 (1990) 1120-1122
21. Haan J., Maat-Schieman M.L., van Duinen S.G., Jensson O., Thorsteinsson L., and Roos R.A. Co-localization of beta/A4 and cystatin C in cortical blood vessels in Dutch, but not in Icelandic hereditary cerebral hemorrhage with amyloidosis. Acta Neurol. Scand. 89 (1994) 367-371
22. Davis J., and Van Nostrand W.E. Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 2996-3000
23. Kalaria R.N., Cohen D.L., Greenberg B.D., Savage M.J., Bogdanovic N.E., Winblad B., Lannfelt L., and Adem A. Abundance of the longer A beta 42 in neocortical and cerebrovascular amyloid beta deposits in Swedish familial Alzheimer's disease and Down's syndrome. NeuroReport 7 (1996) 1377-1381
24. Bornebroek M., Haan J., Van Duinen S.G., Maat-Schieman M.L., Van Buchem M.A., Bakker E., Van Broeckhoven C., and Roos R.A. Dutch hereditary cerebral amyloid angiopathy: structural lesions and apolipoprotein E genotype. Ann. Neurol. 41 (1997) 695-698
25. Vinters H.V., Natte R., Maat-Schieman M.L., van Duinen S.G., Hegeman-Kleinn I., Welling-Graafland C., Haan J., and Roos R.A. Secondary microvascular degeneration in amyloid angiopathy of patients with hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCHWA-D). Acta Neuropathol. 95 (1998) 235-244
26. Wei L., Berman Y., Castano E.M., Cadene M., Beavis R.C., Devi L., and Levy E. Instability of the amyloidogenic cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type. J. Biol. Chem. 273 (1998) 11806-11814
27. Johnson N.A., Jahng G.H., Weiner M.W., Miller B.L., Chui H.C., Jagust W.J., Gorno-Tempini M.L., and Schuff N. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 234 (2005) 851-859
28. Cirrito J.R., Deane R., Fagan A.M., Spinner M.L., Parsadanian M., Finn M.B., Jiang H., Prior J.L., Sagare A., Bales K.R., Paul S.M., Zlokovic B.V., Piwnica-Worms D., and Holtzman D.M. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest. 115 (2005) 3285-3290
29. Deane R., Sagare A., Hamm K., Parisi M., LaRue B., Guo H., Wu Z., Holtzman D.M., and Zlokovic B.V. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J. Neurosci. 25 (2005) 11495-11503
30. Deane R., Sagare A., and Zlokovic B.V. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Curr. Pharm. Des. 14 (2008) 1601-1605
31. Gray F., Dubas F., Roullet E., and Escourolle R. Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy. Ann. Neurol. 18 (1985) 54-59
32. Ishihara T., Takahashi M., Yokota T., Yamashita Y., Gondo T., Uchino F., and Iwamoto N. The significance of cerebrovascular amyloid in the aetiology of superficial (lobar) cerebral haemorrhage and its incidence in the elderly population. J. Pathol. 165 (1991) 229-234
33. Ellis R.J., Olichney J.M., Thal L.J., Mirra S.S., Morris J.C., Beekly D., and Heyman A. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience. Part XV. Neurology 46 (1996) 1592-1596
34. Bergeron C., Ranalli P.J., and Miceli P.N. Amyloid angiopathy in Alzheimer's disease. Can. J. Neurol. Sci. 14 (1987) 564-569
35. Vinters H.V. Cerebral amyloid angiopathy. A critical review. Stroke 18 (1987) 311-324
36. Vonsattel J.P., Myers R.H., Hedley-Whyte E.T., Ropper A.H., Bird E.D., and Richardson Jr. E.P. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann. Neurol. 30 (1991) 637-649
37. Greenberg S.M., Vonsattel J.P., Stakes J.W., Gruber M., and Finklestein S.P. The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Neurology 43 (1993) 2073-2079
38. Olichney J.M., Hansen L.A., Hofstetter C.R., Grundman M., Katzman R., and Thal L.J. Cerebral infarction in Alzheimer's disease is associated with severe amyloid angiopathy and hypertension. Arch. Neurol. 52 (1995) 702-708
39. Claudio L. Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathol. 91 (1996) 6-14
40. Kawai M., Kalaria R.N., Cras P., Siedlak S.L., Velasco M.E., Shelton E.R., Chan H.W., Greenberg B.D., and Perry G. Degeneration of vascular muscle cells in cerebral amyloid angiopathy of Alzheimer disease. Brain Res. 623 (1993) 142-146
41. Rozemuller A.J., Roos R.A., Bots G.T., Kamphorst W., Eikelenboom P., and Van Nostrand W.E. Distribution of beta/A4 protein and amyloid precursor protein in hereditary cerebral hemorrhage with amyloidosis-Dutch type and Alzheimer's disease. Am. J. Pathol. 142 (1993) 1449-1457
42. Van Nostrand W.E., Davis-Salinas J., and Saporito-Irwin S.M. Amyloid beta-protein induces the cerebrovascular cellular pathology of Alzheimer's disease and related disorders. Ann. N. Y. Acad. Sci. 777 (1996) 297-302
43. Van Nostrand W.E., Melchor J.P., and Ruffini L. Pathologic amyloid beta-protein cell surface fibril assembly on cultured human cerebrovascular smooth muscle cells. J Neurochem 70 (1998) 216-223
44. Joachim C.L., and Selkoe D.J. The seminal role of beta-amyloid in the pathogenesis of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 6 (1992) 7-34
45. Maat-Schieman M.L., van Duinen S.G., Bornebroek M., Haan J., and Roos R.A. Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): II-A review of histopathological aspects. Brain Pathol. 6 (1996) 115-120
46. Vinters H.V., Wang Z.Z., and Secor D.L. Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain Pathol. 6 (1996) 179-195
47. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359 (1992) 322-325
48. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., Slunt H.H., Wang R., Seeger M., Levey A.I., Gandy S.E., Copeland N.G., Jenkins N.A., Price D.L., Younkin S.G., and Sisodia S.S. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17 (1996) 1005-1013
49. Lemere C.A., Blusztajn J.K., Yamaguchi H., Wisniewski T., Saido T.C., and Selkoe D.J. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3 (1996) 16-32
50. Maruyama K., Tomita T., Shinozaki K., Kume H., Asada H., Saido T.C., Ishiura S., Iwatsubo T., and Obata K. Familial Alzheimer's disease-linked mutations at Val717 of amyloid precursor protein are specific for the increased secretion of A beta 42(43). Biochem. Biophys. Res. Commun. 227 (1996) 730-735
51. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., and Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2 (1996) 864-870
52. Akiyama H., Mori H., Sahara N., Kondo H., Ikeda K., Nishimura T., Oda T., and McGeer P.L. Variable deposition of amyloid beta-protein (A beta) with the carboxy-terminus that ends at residue valine40 (A beta 40) in the cerebral cortex of patients with Alzheimer's disease: a double-labeling immunohistochemical study with antibodies specific for A beta 40 and the A beta that ends at residues alanine42/threonine43 (A beta 42). Neurochem. Res. 22 (1997) 1499-1506
53. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser P., St George Hyslop P., and Selkoe D.J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 3 (1997) 67-72
54. Natte R., de Boer W.I., Maat-Schieman M.L., Baelde H.J., Vinters H.V., Roos R.A., and van Duinen S.G. Amyloid beta precursor protein-mRNA is expressed throughout cerebral vessel walls. Brain Res. 828 (1999) 179-183
55. Zlokovic B.V., Yamada S., Holtzman D., Ghiso J., and Frangione B. Clearance of amyloid beta-peptide from brain: transport or metabolism?. Nat. Med. 6 (2000) 718-719
56. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M.B., Holtzman D.M., and Zlokovic B.V. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118 (2008) 4002-4013
57. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., and Zlokovic B.V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106 (2000) 1489-1499
58. Iwata N., Mizukami H., Shirotani K., Takaki Y., Muramatsu S., Lu B., Gerard N.P., Gerard C., Ozawa K., and Saido T.C. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J. Neurosci. 24 (2004) 991-998
59. van Dijk E.J., Prins N.D., Vermeer S.E., Hofman A., van Duijn C.M., Koudstaal P.J., and Breteler M.M. Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann. Neurol. 55 (2004) 570-575
60. Gurol M.E., Irizarry M.C., Smith E.E., Raju S., Diaz-Arrastia R., Bottiglieri T., Rosand J., Growdon J.H., and Greenberg S.M. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 66 (2006) 23-29
61. Li Q.X., Berndt M.C., Bush A.I., Rumble B., Mackenzie I., Friedhuber A., Beyreuther K., and Masters C.L. Membrane-associated forms of the beta A4 amyloid protein precursor of Alzheimer's disease in human platelet and brain: surface expression on the activated human platelet. Blood 84 (1994) 133-142
62. Chen M., Inestrosa N.C., Ross G.S., and Fernandez H.L. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem. Biophys. Res. Commun. 213 (1995) 96-103
63. Smith C.C. Stimulated release of the beta-amyloid protein of Alzheimer's disease by normal human platelets. Neurosci. Lett. 235 (1997) 157-159
64. Fryer J.D., Simmons K., Parsadanian M., Bales K.R., Paul S.M., Sullivan P.M., and Holtzman D.M. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 25 (2005) 2803-2810
65. Yankner B.A. Amyloid and Alzheimer's disease-cause or effect?. Neurobiol. Aging 10 (1989) 470-471 discussion 477-478
66. Thomas T., Thomas G., McLendon C., Sutton T., and Mullan M. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380 (1996) 168-171
67. Hase M., Araki S., and Hayashi H. Fragments of amyloid beta induce apoptosis in vascular endothelial cells. Endothelium 5 (1997) 221-229
68. Price D.L., Wong P.C., Borchelt D.R., Pardo C.A., Thinakaran G., Doan A.P., Lee M.K., Martin L.J., and Sisodia S.S. Amyotrophic lateral sclerosis and Alzheimer disease. Lessons from model systems. Rev. Neurol. (Paris) 153 (1997) 484-495
69. Huang S.S., Huang F.W., Xu J., Chen S., Hsu C.Y., and Huang J.S. Amyloid beta-peptide possesses a transforming growth factor-beta activity. J. Biol. Chem. 273 (1998) 27640-27644
70. Jahroudi N., Kitney J., Greenberger J.S., and Bowser R. Endothelial cell dysfunction in response to intracellular overexpression of amyloid precursor protein. J. Neurosci. Res. 54 (1998) 828-839
71. Preston J.E., Hipkiss A.R., Himsworth D.T., Romero I.A., and Abbott J.N. Toxic effects of beta-amyloid(25-35) on immortalised rat brain endothelial cell: protection by carnosine, homocarnosine and beta-alanine. Neurosci. Lett. 242 (1998) 105-108
72. Su G.C., Arendash G.W., Kalaria R.N., Bjugstad K.B., and Mullan M. Intravascular infusions of soluble beta-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage. Brain Res. 818 (1999) 105-117
73. Xu J., Chen S., Ku G., Ahmed S.H., Chen H., and Hsu C.Y. Amyloid beta peptide-induced cerebral endothelial cell death involves mitochondrial dysfunction and caspase activation. J. Cereb. Blood Flow. Metab. 21 (2001) 702-710
74. Yin K.J., Lee J.M., Chen S.D., Xu J., and Hsu C.Y. Amyloid-beta induces Smac release via AP-1/Bim activation in cerebral endothelial cells. J. Neurosci. 22 (2002) 9764-9770
75. Yin K.J., Hsu C.Y., Hu X.Y., Chen H., Chen S.W., Xu J., and Lee J.M. Protein phosphatase 2A regulates bim expression via the Akt/FKHRL1 signaling pathway in amyloid-beta peptide-induced cerebrovascular endothelial cell death. J. Neurosci. 26 (2006) 2290-2299
76. Hsu M.J., Hsu C.Y., Chen B.C., Chen M.C., Ou G., and Lin C.H. Apoptosis signal-regulating kinase 1 in amyloid beta peptide-induced cerebral endothelial cell apoptosis. J. Neurosci. 27 (2007) 5719-5729
77. Davis-Salinas J., and Van Nostrand W.E. Amyloid beta-protein aggregation nullifies its pathologic properties in cultured cerebrovascular smooth muscle cells. J. Biol. Chem. 270 (1995) 20887-20890
78. Xu J., Chen S., Ahmed S.H., Chen H., Ku G., Goldberg M.P., and Hsu C.Y. Amyloid-beta peptides are cytotoxic to oligodendrocytes. J. Neurosci. 21 (2001) RC118
79. Lee J.T., Xu J., Lee J.M., Ku G., Han X., Yang D.I., Chen S., and Hsu C.Y. Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 164 (2004) 123-131
80. Yang D.I., Yeh C.H., Chen S., Xu J., and Hsu C.Y. Neutral sphingomyelinase activation in endothelial and glial cell death induced by amyloid beta-peptide. Neurobiol. Dis. 17 (2004) 99-107
81. Banks W.A., Kastin A.J., and Michals E.A. Selective transport across the blood-brain barrier. Ann. Intern. Med. 105 (1986) 472
82. Blanc E.M., Toborek M., Mark R.J., Hennig B., and Mattson M.P. Amyloid beta-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. J. Neurochem. 68 (1997) 1870-1881
83. Zhang F., Eckman C., Younkin S., Hsiao K.K., and Iadecola C. Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J. Neurosci. 17 (1997) 7655-7661
84. Iadecola C., Zhang F., Niwa K., Eckman C., Turner S.K., Fischer E., Younkin S., Borchelt D.R., Hsiao K.K., and Carlson G.A. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 2 (1999) 157-161
85. Shen M.Y., Hsiao G., Fong T.H., Chen H.M., Chou D.S., Lin C.H., Sheu J.R., and Hsu C.Y. Amyloid beta peptide-activated signal pathways in human platelets. Eur. J. Pharmacol. 588 (2008) 259-266
86. Giri R., Shen Y., Stins M., Du Yan S., Schmidt A.M., Stern D., Kim K.S., Zlokovic B., and Kalra V.K. beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am. J. Physiol. Cell. Physiol. 279 (2000) C1772-C1781
87. Giri R.K., Rajagopal V., Shahi S., Zlokovic B.V., and Kalra V.K. Mechanism of amyloid peptide induced CCR5 expression in monocytes and its inhibition by siRNA for Egr-1. Am. J. Physiol. Cell Physiol. 289 (2005) C264-C276
88. Wu Z., Guo H., Chow N., Sallstrom J., Bell R.D., Deane R., Brooks A.I., Kanagala S., Rubio A., Sagare A., Liu D., Li F., Armstrong D., Gasiewicz T., Zidovetzki R., Song X., Hofman F., and Zlokovic B.V. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat. Med. 11 (2005) 959-965
89. Mueggler T., Baumann D., Rausch M., Staufenbiel M., and Rudin M. Age-dependent impairment of somatosensory response in the amyloid precursor protein 23 transgenic mouse model of Alzheimer's disease. J. Neurosci. 23 (2003) 8231-8236
90. Zlokovic B.V. Vascular disorder in Alzheimer's disease: role in pathogenesis of dementia and therapeutic targets. Adv. Drug Deliv. Rev. 54 (2002) 1553-1559
91. Mackic J.B., Bading J., Ghiso J., Walker L., Wisniewski T., Frangione B., and Zlokovic B.V. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vasc. Pharmacol. 38 (2002) 303-313
92. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
93. Kroemer G., Dallaporta B., and Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu. Rev. Physiol. 60 (1998) 619-642
94. Cho D.H., Nakamura T., Fang J., Cieplak P., Godzik A., Gu Z., and Lipton S.A. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 324 (2009) 102-105
95. Zhang X.D., Wang Y., Zhang X., Han R., Wu J.C., Liang Z.Q., Gu Z.L., Han F., Fukunaga K., and Qin Z.H. p53 mediates mitochondria dysfunction-triggered autophagy activation and cell death in rat striatum. Autophagy 5 3 (2009) 339-350
96. Fiskum G., Murphy A.N., and Beal M.F. Mitochondria in neurodegeneration: acute ischemia and chronic neurodegenerative diseases. J. Cereb. Blood Flow. Metab. 19 (1999) 351-369
97. Beal M.F. Mitochondrial dysfunction in neurodegenerative diseases. Biochim. Biophys. Acta 1366 (1998) 211-223
98. Schapira A.H. Mitochondrial dysfunction in neurodegenerative disorders. Biochim. Biophys. Acta 1366 (1998) 225-233
99. Murphy A.N., Fiskum G., and Beal M.F. Mitochondria in neurodegeneration: bioenergetic function in cell life and death. J. Cereb. Blood Flow. Metab. 19 (1999) 231-245
100. Wallace D.C. Mitochondrial diseases in man and mouse. Science 283 (1999) 1482-1488
101. Sutton E.T., Hellermann G.R., and Thomas T. beta-amyloid-induced endothelial necrosis and inhibition of nitric oxide production. Exp. Cell Res. 230 (1997) 368-376
102. Crawford F., Suo Z., Fang C., and Mullan M. Characteristics of the in vitro vasoactivity of beta-amyloid peptides. Exp. Neurol. 150 (1998) 159-168
103. Schapira A.H. Oxidative stress and mitochondrial dysfunction in neurodegeneration. Curr. Opin. Neurol. 9 (1996) 260-264
104. Bruce-Keller A.J., Begley J.G., Fu W., Butterfield D.A., Bredesen D.E., Hutchins J.B., Hensley K., and Mattson M.P. Bcl-2 protects isolated plasma and mitochondrial membranes against lipid peroxidation induced by hydrogen peroxide and amyloid beta-peptide. J. Neurochem. 70 (1998) 31-39
105. Yin K.J., Lee J.M., Chen H., Xu J., and Hsu C.Y. Abeta25-35 alters Akt activity, resulting in Bad translocation and mitochondrial dysfunction in cerebrovascular endothelial cells. J. Cereb. Blood Flow. Metab. 25 (2005) 1445-1455
106. Chung Y.M., Lee S.B., Kim H.J., Park S.H., Kim J.J., Chung J.S., and Yoo Y.D. Replicative senescence induced by Romo1-derived reactive oxygen species. J. Biol. Chem. 283 (2008) 33763-33771
107. Sanchez A.M., Malagarie-Cazenave S., Olea N., Vara D., Chiloeches A., and Diaz-Laviada I. Apoptosis induced by capsaicin in prostate PC-3 cells involves ceramide accumulation, neutral sphingomyelinase, and JNK activation. Apoptosis 12 (2007) 2013-2024
108. Noe J., Petrusca D., Rush N., Deng P., Vandemark M., Berdyshev E., Gu Y., Smith P., Schweitzer K., Pilewsky J., Natarajan V., Xu Z., Obhukov A.G., and Petrache I. CFTR regulation of intracellular pH and ceramides is required for lung endothelial cell apoptosis. Am. J. Respir. Cell Mol. Biol. 41 3 (2009) 314-323
109. Xu J., Yeh C.H., Chen S., He L., Sensi S.L., Canzoniero L.M., Choi D.W., and Hsu C.Y. Involvement of de novo ceramide biosynthesis in tumor necrosis factor-alpha/cycloheximide-induced cerebral endothelial cell death. J. Biol. Chem. 273 (1998) 16521-16526
110. Pehar M., Vargas M.R., Robinson K.M., Cassina P., Diaz-Amarilla P.J., Hagen T.M., Radi R., Barbeito L., and Beckman J.S. Mitochondrial superoxide production and nuclear factor erythroid 2-related factor 2 activation in p75 neurotrophin receptor-induced motor neuron apoptosis. J. Neurosci. 27 (2007) 7777-7785
111. Yabu T., Imamura S., Yamashita M., and Okazaki T. Identification of Mg2+-dependent neutral sphingomyelinase 1 as a mediator of heat stress-induced ceramide generation and apoptosis. J. Biol. Chem. 283 (2008) 29971-29982
112. Venable M.E., Lee J.Y., Smyth M.J., Bielawska A., and Obeid L.M. Role of ceramide in cellular senescence. J. Biol. Chem. 270 (1995) 30701-30708
113. Carre J.B., Morand O., Homayoun P., Roux F., Bourre J.M., and Baumann N. Purified rat brain microvessels exhibit both acid and neutral sphingomyelinase activities. J. Neurochem. 52 (1989) 1294-1299
114. Jiang G., den Hertog J., and Hunter T. Receptor-like protein tyrosine phosphatase alpha homodimerizes on the cell surface. Mol. Cell. Biol. 20 (2000) 5917-5929
115. Ray R.M., Bhattacharya S., and Johnson L.R. Protein phosphatase 2A regulates apoptosis in intestinal epithelial cells. J. Biol. Chem. 280 (2005) 31091-31100
116. Silverstein A.M., Barrow C.A., Davis A.J., and Mumby M.C. Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 4221-4226
117. Roy S.S., Madesh M., Davies E., Antonsson B., Danial N., and Hajnoczky G. Bad targets the permeability transition pore independent of Bax or Bak to switch between Ca2+-dependent cell survival and death. Mol. Cell 33 (2009) 377-388
118. Steinberg R., Harari O.A., Lidington E.A., Boyle J.J., Nohadani M., Samarel A.M., Ohba M., Haskard D.O., and Mason J.C. A protein kinase Cepsilon-anti-apoptotic kinase signaling complex protects human vascular endothelial cells against apoptosis through induction of Bcl-2. J. Biol. Chem. 282 (2007) 32288-32297
119. Mathews M.T., and Berk B.C. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 711-717
120. Lu J., Yang J.H., Burns A.R., Chen H.H., Tang D., Walterscheid J.P., Suzuki S., Yang C.Y., Sawamura T., and Chen C.H. Mediation of electronegative low-density lipoprotein signaling by LOX-1: a possible mechanism of endothelial apoptosis. Circ. Res. 104 (2009) 619-627
121. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., and Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 (1995) 785-789
122. Brunet A., Datta S.R., and Greenberg M.E. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol. 11 (2001) 297-305
123. Zhao H., Sapolsky R.M., and Steinberg G.K. Phosphoinositide-3-kinase/akt survival signal pathways are implicated in neuronal survival after stroke. Mol. Neurobiol. 34 (2006) 249-270
124. Miyawaki T., Ofengeim D., Noh K.M., Latuszek-Barrantes A., Hemmings B.A., Follenzi A., and Zukin R.S. The endogenous inhibitor of Akt, CTMP, is critical to ischemia-induced neuronal death. Nat. Neurosci. 12 (2009) 618-626
125. Reed J.C. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 111 (2008) 3322-3330
126. Obexer P., Hagenbuchner J., Unterkircher T., Sachsenmaier N., Seifarth C., Bock G., Porto V., Geiger K., and Ausserlechner M. Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis. Mol. Biol. Cell 20 (2009) 2041-2048
127. Willis S.N., and Adams J.M. Life in the balance: how BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol. 17 (2005) 617-625
128. Chen S., Lee J.M., Zeng C., Chen H., Hsu C.Y., and Xu J. Amyloid beta peptide increases DP5 expression via activation of neutral sphingomyelinase and JNK in oligodendrocytes. J. Neurochem. 97 (2006) 631-640
129. Nagai H., Noguchi T., Takeda K., and Ichijo H. Pathophysiological roles of ASK1-MAP kinase signaling pathways. J. Biochem. Mol. Biol. 40 (2007) 1-6
130. Yan S.D., Fu J., Soto C., Chen X., Zhu H., Al-Mohanna F., Collison K., Zhu A., Stern E., Saido T., Tohyama M., Ogawa S., Roher A., and Stern D. An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature 389 (1997) 689-695
131. Li M., Shang D.S., Zhao W.D., Tian L., Li B., Fang W.G., Zhu L., Man S.M., and Chen Y.H. Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. J. Immunol. 182 (2009) 5778-5788
132. Wang H.Y., Lee D.H., D'Andrea M.R., Peterson P.A., Shank R.P., and Reitz A.B. beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J. Biol. Chem. 275 (2000) 5626-5632
133. Le Y., Oppenheim J.J., and Wang J.M. Pleiotropic roles of formyl peptide receptors. Cytokine Growth Factor Rev. 12 (2001) 91-105
134. Yaar M., Zhai S., Fine R.E., Eisenhauer P.B., Arble B.L., Stewart K.B., and Gilchrest B.A. Amyloid beta binds trimers as well as monomers of the 75-kDa neurotrophin receptor and activates receptor signaling. J. Biol. Chem. 277 (2002) 7720-7725
135. Pasquier F., and Delacourte A. Non-Alzheimer degenerative dementias. Curr. Opin. Neurol. 11 (1998) 417-427